The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A study of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft tissue sarcoma.
 
Sant P. Chawla
Honoraria - Amgen; Cytrax; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Consulting or Advisory Role - Amgen; Cytrax; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Amgen; Cytrax; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
Travel, Accommodations, Expenses - Amgen; Cytrax; Johnson & Johnson; Morphotek; PharmaMar; Threshold Pharmaceuticals; TRACON Pharma
 
Patrick Schoffski
Honoraria - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; ITeos Therapeutics; Mundipharma; Novartis; Pique; Plexxikon; Prime Oncology; SERVIER; Swedish Orphan Biovitrum; Threshold Pharmaceuticals; ThromboGenics
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Iteos Therapeutics; Mundipharma; Novartis; Pique; Plexxikon; SERVIER; Swedish Orphan Biovitrum; Threshold Pharmaceuticals; ThromboGenics (I)
Speakers' Bureau - GlaxoSmithKline; Novartis; Prime Therapeutics; Swedish Orphan Biovitrum
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Novartis; PharmaMar; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Novartis; PharmaMar; PharmaMar; Roche
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst)
 
Robin Lewis Jones
No Relationships to Disclose
 
Hans Gelderblom
No Relationships to Disclose
 
Steven Attia
Consulting or Advisory Role - EMD Serono
Research Funding - AB Science (Inst); CytRx Corporation (Inst); Infinity Pharmaceuticals (Inst); Morphotek (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst); ZIOPHARM Oncology (Inst)
 
Bartosz Chmielowski
Honoraria - Amgen; Merck
Consulting or Advisory Role - Amgen (Inst); Astellas Pharma (Inst); Genentech (Inst); Lilly (Inst); Merck/Schering Plough (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Genentech/Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck
 
Brian Andrew Van Tine
Honoraria - Avantis Medical Systems; DFINE; EMD Serono; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis; ZIOPHARM Oncology
Consulting or Advisory Role - Avantis Medical Systems; DFINE; EMD Serono; GlaxoSmithKline; Johnson & Johnson; Lilly; Novartis; ZIOPHARM Oncology
Speakers' Bureau - Caris Life Sciences; DFINE; GlaxoSmithKline
Research Funding - Polaris
Expert Testimony - AB Science
 
Jonathan C. Trent
Consulting or Advisory Role - Bayer/Onyx; GlaxoSmithKline
 
Shreyaskumar Patel
Consulting or Advisory Role - CytRx Corporation; Janssen; Novartis
Research Funding - Eisai; Janssen; Morphotek
 
Andrew J. Wagner
Consulting or Advisory Role - Novartis; Plexxikon
Research Funding - Astex Pharmaceuticals; Genentech; ImClone Systems; Infinity Pharmaceuticals; Merck; Morphotek; Novartis; Sanofi
 
James Kert Viele
Consulting or Advisory Role - Berry Consultants
 
Rashmi Chugh
Research Funding - Biomarin; Lilly; MabVax; Morphotek; Novartis
 
Axel Le Cesne
No Relationships to Disclose
 
Gabriel Tinoco
No Relationships to Disclose
 
Kamalesh Kumar Sankhala
No Relationships to Disclose
 
Julianne Falcone
Employment - Morphotek
Travel, Accommodations, Expenses - Morphotek
 
Charles Schweizer
Employment - Morphotek
Leadership - Morphotek
Research Funding - Morphotek
Travel, Accommodations, Expenses - Morphotek
 
Susan Weil
Employment - Morphotek
Leadership - Morphotek
Travel, Accommodations, Expenses - Morphotek
 
Robert G. Maki
Stock and Other Ownership Interests - Agios; Celgene; Epizyme; Gilead Sciences; Karyopharm Therapeutics
Consulting or Advisory Role - Arcus Ventures; Bayer; Eisai; Gem Pharmaceuticals; GlaxoSmithKline; Lilly/ImClone; SARC: Sarcoma Alliance for Research though Collaboration; TRACON Pharma
Research Funding - Eisai (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book.
Travel, Accommodations, Expenses - Bayer/Onyx; Janssen Oncology